Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib have?
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib has 14 citations in the OpenAlex counts ScholarIQ stores.
When was Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib published?
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib has 2020 year in the ScholarIQ index.
What is the open-access status of Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib?
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib has diamond oa status in the ScholarIQ index.
What is the DOI of Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib?
The DOI for Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib is on the source record.
What is the PMID of Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib?
The PMID for Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib is on the source record.
What is the OpenAlex record for Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib?
The OpenAlex for Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib is on the source record.